Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00086970
- Locations
- πΊπΈ
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors
- Conditions
- First Posted Date
- 2004-07-08
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003198
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 43
- Registration Number
- NCT00002804
- Locations
- πΊπΈ
Via Christi Regional Medical Center, Wichita, Kansas, United States
πΊπΈMBCCOP - LSU Medical Center, New Orleans, Louisiana, United States
πΊπΈUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-06-30
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00002565
- Locations
- πΊπΈ
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
π§π·Faculdade de Medicina do ABC, Sao Paulo, Brazil
π¨π±Clinica Alemana, Santiago, Chile
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: cytarabineDrug: dexamethasoneDrug: etoposideDrug: idarubicinDrug: ifosfamideDrug: leucovorin calciumDrug: mesnaDrug: pegaspargaseDrug: therapeutic hydrocortisoneDrug: thioguanineDrug: vincristine sulfateRadiation: low-LET electron therapyRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET photon therapyDrug: Methotrexate
- First Posted Date
- 2004-06-23
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 120
- Registration Number
- NCT00002816
- Locations
- πΊπΈ
Children's National Medical Center, Washington, District of Columbia, United States
πΊπΈMemorial Sloan-Kettering Cancer Center, New York, New York, United States
πΊπΈKaplan Cancer Center, New York, New York, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 36
- Registration Number
- NCT00003860
- Locations
- π«π·
Hopitaux Universitaire de Strasbourg, Strasbourg, France
π«π·Institut Gustave Roussy, Villejuif, France
π«π·CHRU de Nancy - Hopitaux de Brabois, Vandoeuvre-Les-Nancy, France
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
- Conditions
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 111
- Registration Number
- NCT00004061
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00003575
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈUniversity Hospital/New Jersey Cancer Center, Newark, New Jersey, United States
πΊπΈUSC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00004132
- Locations
- πΊπΈ
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
- Conditions
- First Posted Date
- 2004-05-12
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 500
- Registration Number
- NCT00002802
- Locations
- π©πͺ
University of Cologne, Frechen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.